Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development | Therapeutic Innovation and Regulatory Science | 2020 | 17 |
Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases | Clinical Pharmacology and Therapeutics | 2020 | 14 |
Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017 | Therapeutic Innovation and Regulatory Science | 2020 | 3 |
The Financial Benefits of Faster Development Times: Integrated Formulation Development, Real-Time Manufacturing, and Clinical Testing | Therapeutic Innovation and Regulatory Science | 2020 | 2 |
Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient | Clinical Therapeutics | 2020 | 2 |
Establishing Consensus Understanding of the Barriers to Drug Development in Lupus | Therapeutic Innovation and Regulatory Science | 2020 | 2 |
Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials | Therapeutic Innovation and Regulatory Science | 2020 | 1 |
Assessing Outsourcing Oversight Practices and Performance | Therapeutic Innovation and Regulatory Science | 2020 | 1 |
Research and Development Costs of New Drugs | JAMA - Journal of the American Medical Association | 2020 | 1 |
Benchmarking the Vendor Qualification Process | Therapeutic Innovation and Regulatory Science | 2020 | |
AB1338-HPR GLOBAL PATIENT PERSPECTIVE ON TOP CHALLENGES IN LUPUS CARE AND RESEARCH PARTICIPATION | Annals of the Rheumatic Diseases | 2020 | |